TREATMENT OF LATE-LINE HRD+ ADVANCED OVARIAN CANCER AFTER THREE OR MORE CHEMOTHERAPIES WITH ZEJULA

Dosing Information From the
QUADRA Trial


Starting Dose

The approved starting dose of ZEJULA for treatment of HRD+ advanced ovarian cancer is 300 mg/day1

ZEJULA recommended dose modifications for adverse reactions1

Dose modifications
Dose modifications

For patients with moderate hepatic impairment, reduce the starting dosage of ZEJULA to 200 mg once daily. Monitor patients for hematologic toxicity and reduce the dose further, if needed.


Dose reduction or Interruption

Adverse reactions in QUADRA led to1:

Dose reduction or interruption, 73%

Most frequently from:

  • Thrombocytopenia, 40%
  • Anemia, 21%
  • Nausea, 13%
  • Neutropenia, 11%
  • Vomiting, 11%
  • Fatigue, 9%
  • Abdominal Pain, 5%

Discontinuation, 21%